Sloning BioTechnology Successfully Generated a Unique Type of Gene Mutant Library for Novozymes
News Sep 27, 2007
Sloning BioTechnology GmbH, the provider of enabling technologies for protein engineering applications, has successfully synthesised a unique gene mutant library (SlonoMax™ - Screen) for Novozymes A/S.
Sloning utilised its unique Slonomics™ gene synthesis technology to introduce several individual codons at specific positions of a gene sequence in a clearly defined ratio.
Novozymes will now use the library for screening applications to identify enzymes with significantly improved characteristics.
“We are very delighted by this collaboration with Novozymes. It gives Sloning the opportunity to demonstrate its capabilities in generating genetic diversity without limitations” stated Dr. Jan Van den Brulle, Head of R&D at Sloning.
Torben V. Borchert, Director of Protein Optimisation at Novozymes commented, “We are impressed by Sloning’s ability to precisely meet our sophisticated design specifications. We are very excited to learn how the use of such new types of designed libraries will influence our protein optimization processes”.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.
CRISPR Causes More Genome Damage Than First ThoughtNews
Researchers have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.